| Trial ID # | NCT03355976; BrUOG 354 |
| Phase | II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/CTLA-4 |
| Drug Name | Ipilimumab |
| Alternate Drug Names | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy |
| Drugs in Trial | Ipilimumab, Nivolumab |
| Eligible Participant | Recurrent clear cell ovarian and gynecologic cancer |
| Patients Enrolled | 44, median 1 prior therapies (1-7); 36 OCCC |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Randomized |
| Endpoints | ORR, DoR, PFS, OS, evaluated per RECIST |
| Efficacy | Ipi+Niv (n=30) vs Niv (n=14): ORR: 33.3 (4CR, 6PR) vs 14.3% (2PR) |
| Clinically Significant Adverse Events | Ipi+Niv vs Niv: |
| Conclusion | Ipillimumab+nivolumab demonstrates important, meaningful, and durable activity in people with previously treated ovarian and gynecologic clear cell cancer |
| Reference | Dizon D et al. Final results of BrUOG 354: a randomized phase II trial of nivolumab alone or in combination with ipilimumab with ovarian and extra-renal clear cell carcinomas. J Clin Oncol 2024; 42 (suppl 17):LBA5500. |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.